Our study revealed that PROTAC treatment is also very useful and efficient in luminal p53-mutated BC cells as well, whereas the mdm2 inhibitor AMG-232 was practically ineffectual in inhibiting the cell cycle progress in p53 defective cells. Here, TP53 is linked to breast cancer.